Skip to content
akaturk Academic measurement

Academician

MUSTAFA KORKMAZ

ÖĞRETİM GÖREVLİSİ (Unvan:Doçent) (UYGULAMALI BİRİM)

SÜLEYMAN DEMİREL ÜNİVERSİTESİ TIP FAKÜLTESİ DAHİLİ TIP BİLİMLERİ BÖLÜMÜ

  • Ana Dal Sağlık Bilimleri Temel Alanı
  • Yan Dal Tıbbi Onkoloji (İç Hastalıkları)

A quick look at recorded outputs — details below.

  • Articles 45
  • Projects 0
  • Books 0
  • Proceedings 0
  • Patents 0
  • Artistic 0
Scopus (SJR) Q1 9 Q2 2 Q3 18 Q4 7
WoS (JCR) Q1 2 Q2 5 Q3 8 Q4 18
TR Index 8 articles

Field+year+type normalized OpenAlex percentiles — not Clarivate ESI / SciVal.

Top 1% articles 0
Top 10% articles 0
Avg percentile 11.9%
Top 1% share 0.0%
Top 10% share 0.0%

Articles

Articles with YÖKSİS and OpenAlex source split; narrow by quartile or TR Index.

Index filters

45 publications total

Article list

  1. 2025 Comparison of granisetron and palonosetron in triplet anti-emetic prophylaxis in non-small cell lung cancer patients receiving cisplatin-based highly emetogenic chemotherapy Journal of Oncology Pharmacy Practice DOI 10.1177/10781552241279537 YÖKSİS SJR Q3 JCR Q4
  2. 2025 Tarlatamab in Small-Cell Lung Cancer New England Journal of Medicine DOI 10.1056/NEJMc2511884 YÖKSİS SJR Q1 JCR Q1
  3. 2025 Clinical Outcomes of Adjuvant Chemotherapy in Elderly Patients with Resected Stage II and III Colon Cancer: A Real-life Data Osmangazi Tıp Dergisi DOI 10.20515/otd.1657501 YÖKSİS TR Index
  4. 2024 The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY DOI 10.1007/s10147-023-02460-5 YÖKSİS SJR Q1 JCR Q2
  5. 2024 Can Cytoreductive Nephrectomy Improve Outcomes of Nivolumab Treatment in Patients with Metastatic Clear-Cell Renal Carcinoma? Current Oncology DOI 10.3390/curroncol31090384 YÖKSİS SJR Q2 JCR Q2 OpenAlex 21.1%
  6. 2024 Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study Cancers DOI 10.3390/cancers16122251 YÖKSİS SJR Q1 JCR Q2
  7. 2024 CN33 G-8 geriatric screening tool and geriatric nutritional risk index Annals of Oncology DOI 10.1016/j.annonc.2024.08.428 YÖKSİS SJR Q1 JCR Q1
  8. 2024 Comparison of granisetron and palonosetron in triplet anti-emetic prophylaxis in non-small cell lung cancer patients receiving cisplatin-based highly emetogenic chemotherapy Journal of Oncology Pharmacy Practice DOI 10.1177/10781552241279537 YÖKSİS SJR Q3 JCR Q4
  9. 2024 Metastatik kolorektal kanserli hastalarda bevacizumab ile vücut kitle indeksi arasındaki ilişki Mevlana Medical Sciences DOI 10.56752/Mevmedsci.2024.54 YÖKSİS
  10. 2023 The prognostic role of HIF-1α and NF-κB expression in RAS wild-type metastatic colorectal cancer: A Turkish Oncology Group (TOG) study Journal of Cancer Research and Clinical Oncology DOI 10.1007/s00432-023-04628-y YÖKSİS SJR Q1 JCR Q3
  11. 2023 Extensive metastatic ependymoma with long-term progression-free survival with capecitabine plus temozolomide combination chemotherapy: A case report Journal of Cancer Research and Therapeutics DOI 10.4103/jcrt.jcrt_1664_22 YÖKSİS SJR Q3 JCR Q4
  12. 2023 Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective study Neoplasma DOI 10.4149/neo_2022_221004N984 YÖKSİS SJR Q2 JCR Q3
  13. 2023 Sunitinib-induced small bowel wall edema as a prognostic marker in metastatic renal cell carcinoma Journal of Cancer Research and Therapeutics DOI 10.4103/jcrt.jcrt_899_21 YÖKSİS SJR Q3 JCR Q4
  14. 2023 Low-dose (7.5 mg/kg) bevacizumab may be a viable option in recurrent ovarian cancer: A retrospective study Journal of Cancer Research and Therapeutics DOI 10.4103/jcrt.jcrt_1879_20 YÖKSİS SJR Q3 JCR Q4
  15. 2023 Does red blood cell distribution width predict prognosis in metastatic renal cell carcinoma patients using first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy? Journal of Cancer Research and Therapeutics DOI 10.4103/jcrt.jcrt_898_22 YÖKSİS SJR Q3 JCR Q4
  16. 2023 The prognostic role of HIF-1α and NF-κB expression in RAS wild-type metastatic colorectal cancer: A Turkish Oncology Group (TOG) study Journal of Cancer Research and Clinical Oncology DOI 10.1007/s00432-023-04628-y YÖKSİS SJR Q1 JCR Q3
  17. 2023 A new prognostic factor in patients with recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan: Hemoglobin, albumin, lymphocytes and platelets (HALP) score Archives of Current Medical Research DOI 10.47482/acmr.1175461 YÖKSİS TR Index
  18. 2023 A rare case of kidney loss: urogenital tuberculosis Porto biomedical journal DOI 10.1097/j.pbj.0000000000000201 YÖKSİS SJR Q3
  19. 2023 A new prognostic factor in patients with recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan: Hemoglobin, albumin, lymphocytes and platelets (HALP) score Archives of Current Medical Research DOI 10.47482/acmr.1175461 YÖKSİS TR Index
  20. 2023 Otuz yaş altı meme kanserli kadınların klinikopatolojik özellikleri ve sağkalım sonuçları Akdeniz Medical Journal DOI 10.53394/akd.979443 YÖKSİS TR Index

Back to academicians